Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TD-1473 Long-Term Safety in Ulcerative Colitis
NCT03920254Phase 3Terminated
- Sponsor
- Theravance Biopharma, Inc.
- Start
- Jul 2020
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 22
01
Overview
Phase 3, open-label trial of izencitinib in ulcerative colitis (UC) (3 arms), sponsored by Theravance Biopharma, Inc. Primary endpoint: Number of Participants Who Experienced a Treatment-emergent Adverse Event. Started Jul 2020; status: terminated.
02
Drugs
izencitinib
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03920254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03920254.